This clinical trial is focused on studying a type of lung cancer known as advanced non-small cell lung cancer (NSCLC) that has specific changes in the genes called HER2 mutations. The study is testing a new treatment called BAY 2927088, which is taken as a tablet, to see how well it works and how safe it is compared to the usual treatments. The usual treatments include a combination of medicines such as pembrolizumab, pemetrexed, cisplatin, and carboplatin, which are given through an infusion into a vein.
The purpose of the study is to find out if BAY 2927088 can help patients live longer without their cancer getting worse. Participants in the study will be randomly assigned to receive either the new treatment or the standard treatment. The study will monitor the participants over a period of time to see how their cancer responds to the treatment and to check for any side effects.
Throughout the study, participants will have regular check-ups and tests to track their health and the progress of their cancer. The study aims to provide valuable information on whether BAY 2927088 could be a better option for treating this type of lung cancer in the future.
Austria 
Belgium 
Bulgaria 
Czechia 
Denmark 
Finland 
France 
Germany 
Greece 
Hungary 
Italy 
Poland 
Portugal 
Romania 
Slovakia 
Spain 
Sweden 
The Netherlands 